Administration in vivo of recombinant interleukin 2 (rIL-2) to mice induces a polyclonal IgM response. When co-administered with a specific antigen, rIL-2 can enhance concentrations of murine IgM antibodies specific for the antigen by fivefold within 7 d of initial treatment. IgM antibodies that are induced after injection of rIL-2 include antibodies specific for J5, a cell wall core lipopolysaccharide (LPS) antigen that is shared by the different members of the Enterobactericeae family. We report here that mice pretreated with rIL-2 or immunized with J5 antigen 7 d before bacterial challenge were protected from septic death that is caused by intraperitoneal challenges with Eschefrichia coli. Optimal protection was provided by a combined J5 antigen and rIL-2 treatment. Acquisition of the rIL-2 and J5 antigeninduced protection against lethal bacterial infection coincided temporally with maximal serum IgM titers that also contained IgM antibodies specific for the J5 antigen. In passive immunization experiments, the affinity-purified IgM fraction in sera of rIL-2-treated animals was identified as necessary and sufficient for protection. The IgM-depleted serum had no protective effect. The nonspecific augmentation of host-defense mechanisms without the induction of endotoxin manifestations makes rIL-2 a potential candidate to any alternative LPS-containing vaccines for the prevention of bacterial infections by gram-negative organisms since the core LPS antigen is shared among gram-negative bacteria.
Introduction
Gram-negative bacterial sepsis that is caused by microorganisms ofthe Enterobactericeae family is associated with high morbidity and mortality, especially in immunocompromised hosts (1, 2) who succumb to this infectious syndrome despite appropriate antibiotic therapy. Sequelae of gram-negative bacteremia have been related to the toxicity ofendotoxin, the lipopolysaccharide (LPS) component of the outer membrane (3) . There is experimental evidence that hyperimmune antisera with specificity for the LPS antigens protect animals and humans from the consequences of serious infection by gram-negative organisms (4) (5) (6) (7) (8) . Both anti-endotoxic and anti-bacterial activities of antibodies have been considered as potential mechanisms whereby humoral immunity of the host can modulate the outcome of gram-neg-ative septicemia. The use of endotoxin to induce protective immunity in animals and especially humans, however, has been limited by the highly toxic activity of the endotoxin molecule. Alternative approaches for immunoprophylaxis are required to allow the induction of a protective immune response to gramnegative bacteria that circumvent the major obstacle ofendotoxic manifestations.
We have recently reported that recombinant interleukin 2 (rIL-2)', when given to mice in vivo, can cause a polyclonal IgM response (9) . IgM concentrations after rIL-2 treatment alone reach titers that are similar to those induced directly by immunization with specific antigens. Systemic administration of the lymphokine results in a polyclonal activation of the T cell as well as the B cell compartment. It was the goal of this study to assess the potential efficacy of administering rIL-2 in vivo to protect mice from septic death by pretreatment with lymphokine injections I wk before infection. The protective capacity of rIL-2 pretreatment was compared with the immunity induced by immunization with the LPS core J5 antigen. The J5 antigen is shared among the different members of the Enterobactericeae family. We report here that prior systemic rIL-2 administration to mice prevented septic death after intraperitoneal bacterial challenge with Escherichia coli. Combination of rIL-2 and J5 antigen therapy could further reduce mortality rates. rIL-2 pretreatment maintained its protective efficacy in mice that had been rendered refractory to subsequent bacterial challenges by previous exposure to sublethal LPS doses, which suggests that the IL-2-mediated augmentation of host defense mechanisms was distinct from induction of early phase endotoxin tolerance. Only the affinity-purified IgM fraction of serum induced after rIL-2 administration was identified as the protective serum factor in passive immunization experiments.
Methods
Animals. Female BALB/c mice were obtained from Jackson Laboratory, Bar Harbor, ME. They were used at the age of 6-8 wk and weighed between 18 and 20 g.
Preparation and use ofrIL-2. rIL-2 (batch 9A, 308B) and excipient buffer control were kindly supplied by Cetus Corp., Emeryville, CA (10) . As determined by a Limulus assay, the recombinant product contained < 0.03 ng endotoxin/ 106 U rIL-2. This amount ofLPS in the recombinant product has been determined in our laboratories to be too small to induce bromelin plaques in spleen cells. For all experiments, rIL-2 and excipient buffer control were diluted in RPMI 1640 medium, supplemented with 2% normal mouse serum. All batches were tested for their growth-supporting activities of the IL-2-dependent cell line HT2 in a biological assay before they were used for in vivo experiments.
Antigen and immunizations. E. coli J5 antigen was purchased from List Biological Laboratories, Campbell, CA. The LPS was isolated from J5 antigen in an aqueous solution. Secondary responses were induced by rechallenging at day 14. Sera were collected before and 7 d after each immunization to determine humoral responses. One group of mice was treated with three daily doses ofrIL-2 (5,000 U/injection) intraperitoneally (total dose 45,000 U) in the 3 d after the primary and secondary immunization with J5. This dose has been previously demonstrated to provide maximal IgM polyclonal induction (9) . Another group was not immunized with J5 antigen but was treated with rIL-2 according to this described protocol. Control mice received excipient control buffer instead of rIL-2. Mice were challenged with E. coli on day 7 of the primary response that was also 7 d after the initiation of the rIL-2 treatment (Table I) .
Bacteria. E. coil strain J96 (04:K6:H+) was used for challenge studies.
It had been isolated from a patient with pyelonephritis. J96 is hemolytic, colicin V-positive, and resistant to the bactericidal activity of normal serum (12) . Stock cultures were stored at -70'C in Luria broth with 50% glycerol. For bacterial challenge studies, stock culture was inoculated onto trypticase soy agar plates and incubated at 370C for 20 h. The 20-h cultures were harvested into normal saline and the number of colonyforming units (CFU) was determined from the optical density by using standard growth curves. Standard growth curves were constructed by comparing the optical density of a bacterial suspension in saline at 600 nm (1 cm light path) with the number ofCFU as determined by a standard agar pour technique. The bacterial solutions were calibrated to designated CFU per milliliter and kept on ice until injected intraperitoneally into mice.
Bacterial challenge experiments. Mice were challenged with an intraperitoneal injection ofE. coli through a 27-gauge needle. To determine a lethal dose-response curve, mice received increasing doses of J96 in 1 ml inoculum. Mice were observed at 2-4-h intervals for the first day after infection, and then at 6-h intervals until the experiment was terminated after 5 d. Results from these studies provided a basis to challenge mice with a designated lethal dose. Mice that were immunized with J5 antigen and/or treated with rIL-2 were challenged at day 7 after the immunization or the initiation ofthe treatment with rIL-2 and observed for survival as described. In some experiments, mice were infected with sublethal doses to induce early phase LPS tolerance and then were challenged with twice the 100% lethal dose (LDire) after 24 h. of BALB/c mice with three daily doses of 5,000 U rIL-2 for 3 d (total dose 45,000 U rIL-2) after immunization. Mice were boosted with J5 antigen after 2 wk and again received three daily injections with 5,000 U rIL-2 over three consecutive days (total dose 45,000 U rIL-2). Treatment with rIL-2 in the absence of any antigen or adjuvant was sufficient to induce significant levels of anti-J5 IgM-specific for J5 antigen in the sera oftreated mice. Concentrations of rIL-2-induced IgM antibodies were similar to J5 IgM-specific ELISA titers in J5 immunized mice (Fig. 1) . Addition of rIL-2 to the J5 antigen immunization protocol enhanced the primary IgM anti-J5 response at day 7, but did not further increase IgM titers during the secondary response when compared with the effect of rIL-2 or J5 alone. From the same sera, IgG antibodies specific for J5 were determined. As shown in Fig. 1 , rIL-2 alone did not induce production ofany J5-specific IgG antibodies during either the primary or secondary response. The primary humoral response to J5 immunization was limited to antibodies of the IgM subclass. However, boosting with the glycolipid core J5 antigen caused the production of high titers of IgG anti-J5 antibodies that was not further increased by additional treatment with rIL-2 ( Fig. 1 ). The effect of rIL-2 to induce IgM antibodies after injection in vivo was not selective for an anti-J5 response. As we have recently reported (9), sera of rIL-2-treated mice contain IgM antibodies against multiple antigens (e.g., keyhole limpet hemocyanin, sperm whale myoglobin, or ovalbumin) despite no prior direct immunization with these antigens. Thus, anti-J5 antibodies are included among the polyclonal IgM antibodies produced after rIL-2 administration. Sera from the primary response to rIL-2 contained on the average 1gM, (Table II) : 67% survived compared with 47% ofthe control group.
Significant protection (P < 0.025) was achieved with the administration of rIL-2 alone in vivo 1 wk before the bacterial challenge: 80% of IL-2-treated animals survived infection with lethal doses of E. coli. The most significant protective effect against lethal challenges with E. coli was induced by co-administration of the glycolipid core J5 antigen and rIL-2. 86% of animals pretreated with the combination ofJ5 and rIL-2 survived intraperitoneal challenges with doses ofE. coli that were able to kill 53% of the control mice (Table II) .
The protective capacity of rIL-2 and J5 immunization can be transferred by serum ofpretreated animals. Passive immunization experiments were designed to explore the possibility that factors in sera of rIL-2 injected animals were protective against the fatal outcome of E. coli septicemia. BALB/c mice were treated with a total of 45,000 U rIL-2 given as three 5,000 U daily doses on three consecutive days and sera were collected 4 d after termination of the rIL-2 treatment. Control animals received excipient control buffer solution instead of rIL-2. 0.5 ml pooled serum was injected intraperitoneally into recipient mice 3 h before and again at the time of the challenge with an inoculum ofE. coli that was equal to three times the LD50. 20% of the mice passively immunized with 1 ml of control mouse serum survived this bacterial infection, whereas 100% of mice that had received 1 ml ofserum from rIL-2-treated mice survived this infectious challenge (Table III) . In another set ofexperiments to determine the protective capacity ofpassively transferred sera in mice that subsequently received LD100 doses of E. coli, we injected mice intraperitoneally with sera obtained from the following groups: (1) rIL-2-treated mice, (2) J5 antigen-immunized mice, (3) mice that had been immunized with J5 antigen and treated with rIL-2, or (4) control buffer-treated mice, all as described in Table I . Sera were collected 7 d after the start oftreatment or immunization protocols. IL-2-treated and/or J5-immunized mice contained only IgM, but no IgG that was specific for J5 antigen as determined by ELISA. Passive immunization with sera from J5-immunized or rIL-2-treated mice was able to temporarily postpone the lethal effects of bacterial infection (Fig. BALB/c mice were treated with rIL-2 or buffer control as described in Table I . On day 7, they were killed and serum was collected. Naive BALB/c mice were injected with 0. 3). When these sera were given 3 h before and at the time of subsequent lethal E. coli injection, a greater number of mice survived at 14-18 h after the bacterial challenge (P < 0.05) than mice that received serum from buffer control-treated mice. By 24 h after the bacterial challenge, there was no difference in survival among mice that received different serum preparations.
The IgMfraction in sera ofrIL-2-treated mice has protective activities against death from gram-negative septicemia. The efficacy of injected rIL-2 in preventing death from gram-negative bacteremia correlated with the induction of a humoral IgM immune response. The J5-specific IgM ELISA titers in protective sera ranged between 1:3 and 1:10, with the mean at 1:6. This intriguing correlation between the induction of IgM antibodies and the prevention of death from bacteremia may suggest that IgM antibodies represented at least one of the protective serum fractions. To explore this possibility and to identify serum factors 100 _ HOURS Figure 3 . Sera of mice pretreated with J5 and/or rIL-2 are protective in passive immunization experiments. BALB/c mice (n = 10/group) were treated with control buffer or rIL-2, or were immunized with J5
and then treated with control buffer or rIL-2 as described in Table I .
Sera were collected on day 7, pooled, filtered, and 0.5-ml aliquots were transferred into naive recipient BALB/c mice by an intraperitoneal injection. Recipient mice were challenged with intraperitoneal inocula of E. coli 3 h later together with a second dose of 0.5 ml serum. Each point on the figure represents the overall survival of 10 mice per group at the different time points after the LD100 E. coli injection. by an ELISA system. The IgM-depleted serum fraction was completely devoid of IgM antibodies (data not shown). Sera of rIL-2-treated animals contained about fivefold higher IgM concentrations than that of control animals. The affinity-purified IgM and the IgM-depleted serum fractions were adjusted to volume equivalents of the original sera. Recipient animals were passively immunized with 0.5 ml 3 h before and again at the time of infection with E. coli. All animals that had received the IgM fraction ofrIL-2-treated sera survived intraperitoneally administered LD80 doses of E. coli (Fig. 4) . The IgM preparation from sera ofcontrol animals had lesser protective capacity; mor- (Table IV) . At that time, the animals received a second dose of bacteria that was twice the LD100. Only 1 of 19 remaining animals (5%) in the control group could sustain the repeated bacterial challenge. Mice that were preimmunized with J5 antigen and/or pretreated with rIL-2, however, were all able to survive the second E. coli intraperitoneal dose that was twice the LD100. 67% of J5 immunized animals survived the second intraperitoneal challenge with the very high doses of E. coli (Table IV) ; 50% of the rIL-2-treated mice survived the repeated E. coli dose. Optimal protection was again achieved when rIL-2 and J5 antigen were combined in the pretreatment protocol. Only 4 out of these 25 mice that received a second dose of twice the LD100 died. It is interesting to note in the progress of this study that recent exposure of mice to a sublethal dose of E. coli induced a host response that protected the majority of the previously naive animals from acute septic death when subsequently infected with a single LD100 dose (data not shown).
At least twice the lethal dose of E. coli had to be injected to cause septic death in naive mice that had previously (1 day earlier) received sublethal doses of bacteria. However, under these circumstances, the prior administration of J5 antigen and/or rIL-2 protected BALB/c mice from septic death.
Discussion
Numerous reports have established that preimmunization with the glycolipid core J5 antigen of Enterobactericeae or passively transferred anti-J5 and anti-LPS antibodies provide protection against the fatal sequelae of gram-negative septicemia in a number of experimental animal models and humans. The significant finding of this study is that when rIL-2 was given systemically without any adjuvants, it could substitute for this bacterial core endotoxin antigen or LPS and it was highly effective in protecting animals from septic death after E. coli infection. Although the mechanism of the protection has not been completely clarified, there is a striking correlation between the ability of J5 antigen or rIL-2 to induce IgM antibodies specific for the LPS core J5 antigen and the protective efficacy of both agents. In passive immunization studies, we demonstrated that the protection of the host was mediated by affinity-purified antibodies of the IgM subclass. In comparison with the IgM-depleted fraction of the same serum at equivalent doses, we demonstrated that IgM was necessary and sufficient to protect against lethal E. coli sepsis. However, the possibility exists that during the processing of sera, additional protective humoral components in the nonimmunoglobulin fractions, e.g., acute-phase reactants, may have been destroyed. Our data do suggest that 1gM antibodies directed 1760 Stimulation of protective immunity against gram-negative organisms has been of increasing interest. Polyclonal antisera raised by immunization with smooth bacteria (4) (5) (6) (7) (8) have been successfully used to passively transfer immunity against homologous organisms. Also monoclonal antibodies against 0-side-chain LPS determinants (14) (15) (16) have been shown to have protective capacity in an in vivo bacterial challenge model. However, the usefulness ofantisera for passive immunotherapy in gram-negative bacterial systemic infections has been hampered by the vast heterogeneity found among strains ofgram-negative organisms. Therapeutically useful reagents require cross-reactivity of the antisera with a broad spectrum of bacteria of the Enterobactericeae. For these reasons rough mutants of gramnegative bacteria, like E. coli strain J5, have been used for immunization. The mutants lack the heterogeneous polysaccharide o antigen but express the conserved core of the LPS molecule (17) . Conflicting data have been reported about the protective capacity of these cross-reactive antisera. In several studies, animals could be protected from experimentally induced bacteremias. As (9) and increases total IgM serum levels about fivefold. We have not seen any effect on serum concentrations of IgG after administration of rIL-2 in this study. The mechanism of action of systemically administered rIL-2 in the induction ofpolyclonal 1gM
is not yet clear. Analysis ofantigen-specific precursor frequencies ofproliferative T cells showed that injection ofrIL-2 is followed by a polyclonal T cell activation (9) . The finding that the polyclonal IgM response could be induced in helper T cell-depleted mice and in nude mice suggested as one possibility that rIL-2 might have a direct effect on the B cell compartment. Receptor molecules for IL-2 have been found on a subset of B cell, Lyt1+ B cells (9) . Antibody responses of that B cell subset are limited to antibodies ofthe IgM subclass (19, 20) . Antibody specificities induced by rIL-2 included IgM antibodies against J5 antigen (Fig. 1) . When the IgM fraction of sera ofrIL-2-treated animals was purified by affinity absorption and transferred into naive mouse recipients, the protective efficacy was conferred only by the IgM fraction, not the remaining IgM-depleted serum fraction (Fig. 4) . This suggests that IgM antibodies represent at least one of possibly many protective humoral factors against gram-negative bacterial infections. Protection efficacy against sequelae of gram-negative bacteremia has been described in preimmune rabbit sera (21) . It is likely that this antibacterial immune activity was mediated by spontaneously produced IgM as is demonstrated in our model wherein some protection was provided by affinitypurified IgM from "normal" mice (Fig. 4) (Table IV) . Nevertheless, pretreatment with rIL-2 was effective in protecting repeatedly infected animals from septic death. The efficacy ofrIL-2 protection in mice with early phase LPS tolerance provides evidence that rIL-2 does not represent an LPS-like tolerogen but rather induces protective host immunity by a mechanism different from hyporesponsiveness to LPS. The lymphokine preparation used in the experiments described here is a recombinant product and has been produced in E. coli. One could argue that miniscule amounts of LPS (< 1 pg per IL-2 injection measured in a Limulus assay) were contaminating the IL-2 preparation; however, it did not induce a secondary IgG response to LPS determinants when mice were immunized with rIL-2 and challenged with the same preparation (Fig. 1 ). In the same experiment, mice injected with 50 tig J5 produced high serum IgG titers during the secondary response. Amounts of 10 ng/mouse are usually considered as biologically active doses ofLPS. Since the effect ofJ5 and rIL-2 was additive, contamination ofthe lymphokine solution with at most picogram amounts of LPS did not seem to relate to endotoxin biological activities. Finally, we have measured induction of bromelin plaques in spleen cells of J5 and LPS-treated and rIL-2-treated mice, which is a very sensitive assay system for in vivo LPS effects. rIL-2 equivalent to 106 U did not increase the numbers of plaque-forming cells (data not shown).
rIL-2 has been applied in patients with stage IV tumors and has been tolerated (26, 27) . This, coupled with the finding that rIL-2 is more efficient than a glycolipid core antigen in inducing a protective humoral immune response, makes this lymphokine a suitable candidate for clinical application. In contrast to specific bacterial antigens, the stimulating effect of rIL-2 in protective immunity is polyclonal in nature and should not be hampered by the heterogeneity among members of the Enterobactericeae family. rIL-2 administration alone did not result in the production ofIgG antibodies and did not induce immunologic memory. The protective efficacy seemed to be limited to 1 to 2 wk after termination of rIL-2 administration. We have previously shown that rIL-2 is effective in helper T cell-depleted mice. Thus, the polyclonal activation of IgM-producing B cells was not dependent on a fully competent immune system. The possibility in bacterial infections that IL-2 can stimulate other protective arms of immunity, e.g., cytotoxic T cells and elaboration of acute phase reactants, is now being evaluated. Also, the optimal doses and the kinetics of IL-2-induced immunity demonstrated in this report are being now studied in mice. It should be noted that the amount ofrIL-2 necessary to induce antibody responses in mice would cause endothelial damage in humans if administered parenterally in equivalent amounts per body mass. It is well-known that large amounts of IL-2 administered to humans can cause a capillary leak syndrome. Therefore, instead of evaluating the IL-2 dose humoral responses in mice, a more direct method of determining the IL-2 dose required for humoral responses in humans may entail evaluation in nonhuman primates or humans. In conclusion, the possibility that rIL-2 might be a potential immunoprophylaxis reagent for individuals who develop predictable therapy-induced immunological deficiencies and carry a high risk for gram-negative bacterial septicemias has important clinical implications.
